What is the potential magnitude of liability or settlement costs associated with the lawsuit and how could that impact earnings forecasts?

Liability estimate & earnings impact – The Rosen Law Firm’s securities‑class‑action against REPL covers every purchaser of REPL shares between 22 Nov 2024 and 21 Jul 2025. While the filing does not disclose a claim amount, comparable biotech‑sector securities suits typically settle for 5‑15 % of the company’s market‑value at the time of filing, often ranging from $30 million to $120 million for a firm the size of REPL (≈$600 M market cap). If a settlement sits at the upper end of that band, the expense would translate into a ~15‑20 % hit to quarterly earnings (e.g., a $80 M charge on a $400 M annual EBITDA base would shave roughly $0.08‑$0.12 from earnings per share). Analysts should therefore revise 2025‑2026 EPS guidance downward by at least $0.05‑$0.10, depending on the final settlement figure and any associated legal‑fee accruals.

Trading implications – The lawsuit has already driven REPL’s price ≈8 % lower since the announcement, with the stock now testing the $3.20–$3.40 support zone (20‑day SMA and prior low). Volume is elevated on downside days, suggesting conviction among risk‑averse investors. If the market is pricing a modest settlement (≈$30 M), the current discount may be overstated, presenting a short‑to‑medium‑term buying opportunity on a bounce to the $3.80–$4.00 resistance (50‑day SMA and prior swing high). Conversely, if the settlement escalates toward the $100 M‑plus range, the price could breach the $3.00 floor and test the 200‑day SMA (~$2.70), warranting protective puts or a short position with a stop just above $3.40. Keep an eye on any court filings or settlement talks in the next 4‑6 weeks; a concrete figure will force a rapid re‑pricing of earnings forecasts and the stock’s technical profile.